title: Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder: a meta-analysis.
abstract: The primary objective of this post-hoc analysis was to evaluate the effect of short-term treatment with desvenlafaxine versus placebo on sexual dysfunction (SD), assessed from Arizona Sexual Experiences Scale scores, in adult outpatients with major depressive disorder. Data from three randomized, double-blind, placebo-controlled trials of 50 or 100 mg/day desvenlafaxine for major depressive disorder were pooled. SD status, determined from Arizona Sexual Experiences Scale scores, was assessed at baseline and week 8, last observation carried forward. Subgroup analyses addressed the effects of sex, baseline SD, and antidepressant response. At week 8, last observation carried forward (n=1562), SD rates were 54, 47, and 49% for 50 mg/day desvenlafaxine, 100 mg/day desvenlafaxine, and placebo, respectively [adjusted odds ratios (95% confidence interval) vs. placebo: 1.205 (0.928, 1.564) and 1.129 (0.795, 1.604), respectively]. The treatment by baseline SD interaction approached statistical significance (P=0.0663), mainly driven by poorer scores for desvenlafaxine versus placebo in the 100 mg group. Treatment by sex interactions were not statistically significant. Small but statistically significant treatment by sex interactions were observed for sex drive (P=0.0011) and ease of erection/lubrication (P=0.0151). Although there was no overall effect of desvenlafaxine on SD, a treatment by baseline SD interaction was suggested for 100 mg desvenlafaxine.
authors.affiliation: aDepartment of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville bPfizer Inc., Collegeville, Pennsylvania cDepartment of Psychiatry and Institute for Women's Health, Virginia Commonwealth University, Richmond, Virginia, USA dPfizer Inc., Walton Oaks, UK ePfizer Canada Inc., Kirkland, Quebec, Canada.
authors.forename: Anita H
authors.initials: AH
authors.lastname: Clayton
authors.forename: Eunhee
authors.initials: E
authors.lastname: Hwang
authors.forename: Susan G
authors.initials: SG
authors.lastname: Kornstein
authors.forename: Karen A
authors.initials: KA
authors.lastname: Tourian
authors.forename: Ru-fong
authors.initials: RF
authors.lastname: Cheng
authors.forename: Lucy
authors.initials: L
authors.lastname: Abraham
authors.forename: Linda
authors.initials: L
authors.lastname: Mele
authors.forename: Matthieu
authors.initials: M
authors.lastname: Boucher
mesh_terms: D000328:Adult; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy*; D000069468:Desvenlafaxine Succinate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D007172:Erectile Dysfunction / Q000188:drug therapy; D005260:Female; D006801:Humans; D007989:Libido; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D012737:Sex Factors; D020018:Sexual Dysfunctions, Psychological / Q000188:drug therapy*
chemical_list: D000928:Antidepressive Agents; D000069468:Desvenlafaxine Succinate